Open letter: Requesting Clarification on the Recent Deal on Generic Bedaquiline Supply
Letters • 2023TAG, Partners In Health, and MSF Access Campaign sent an open letter to Johnson & Johnson requesting detailed responses to questions and concerns regarding the deal with the Global Drug Facility to supply generic bedaquiline to low- and middle-income countries that excludes South Africa, 10 EECA countries, and China.
CROI 2023 Tuberculosis Research Round Up
Statement / Press • 2023Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI).
TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Company’s Action Falls Short of Community Demands
Statement / Press • 2023After over a year of sustained advocacy from the TB community demanding that Johnson & Johnson publicly commit to non-enforcement or withdrawal of secondary patents on bedaquiline filed in 66 low- and middle-income countries (LMICs)...
TB Vaccine Development: The Next Chapter Starts Now
Webinars • 2023On Thursday, April 13, Treatment Action Group (TAG) presented this webinar about important developments in TB vaccine research.
Call for Expression of Interest: Community Advisory Boards to Support Community Engagement in Research under the SMART4TB Project
Page • 2023The SMART4TB Consortium is calling for expressions of interest from multi-national community advisory boards (CAB) or similarly organized civil society organizations within three geographic focus areas to support community engagement in research in a new five-year research project funded by USAID.Treatment Action Group Announces Palm Desert Exhibition at Melissa Morgan Fine Art – “35 Years of Art to End AIDS”
Statement / Press • 2023Treatment Action Group (TAG) is pleased to present the exhibition “35 Years of Art to End AIDS” at Melissa Morgan Fine Art in Palm Desert, CA. The exhibition features selected works from TAG’s Limited Art Editions Collection and will run from March 17 through April 7.
Community Call to Action on Equitable Access to Long-Acting Therapies
Statement / Press • 2023The growing pipeline for long-acting therapies and their potential to accelerate various national and global disease elimination goals warrants global community mobilization to ensure equitable access to these therapies.
TB CAB 10-Year Anniversary Evaluation Report 2011–2021 and Podcast
Publication • 2022In 2021, the Global Tuberculosis Community Advisory Board (TB CAB) celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.
LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
Statement / Press • 2022Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.
Activists Across the World Demand Urgent Action to Improve Access to Lifesaving Tuberculosis (TB) Medicine, Bedaquiline
Statement / Press • 2022A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fund’s Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.